Visteon Corporation, an automotive technology company, engages in the design, manufacture, and sale of automotive electronics and connected car solutions for vehicle manufacturers.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 8.33, read 2026-11-05
Ethical passes the values gate
Price77.48 USD
Fair value130.00
Ethical score70.0/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-11-05Read Distribution80.28-3.5% to today ✓Markdown gives way to Distribution after an 18% slide in 7 weeks
2026-09-16Read Markdown97.67-20.7% to today ✓Accumulation gives way to Markdown after a 6% slide in 4 weeks
2026-08-16Read Accumulation104.13-25.6% to today Markup gives way to Accumulation after a 12% slide in 6 weeks
2026-07-02Read Markup118.44-34.6% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Visteon Corporation holds its Distribution at $77.48. The statistical read favours the sellers, held for 3 days.
As held on the ledger · 2026-11-05
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 3 days
Price at the screen
$77.48
Valuation
21.87 trailing · 8.10 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.26
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
12.73%
Below 33%
Interest-bearing debt is just 12.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
40.87%
Below 49%
Money owed to the company is 40.9% of assets, under the 49% limit.
Pass
Revenue purity
0.58%
Below 5%
Only 0.6% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Visteon clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 13%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when VC's ethical verdict changes
Today VC passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 40% discount to our $130.00 fair value, 5.80% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 40.4% discount to the base estimate.
Where our models see it going: fair-value estimate $130.00, with a range of $130.00 to $154.96, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Auto Electronics Supplier Stuck in Low Gear
Picture a new car rolling off the line with glowing screens and connected features. The electronics inside still come from suppliers fighting razor thin margins and lumpy orders tied to vehicle production cycles. Visteon shows a forward P/E of 10.3x and a 56 percent gap to stated fair value, yet the opportunity rating sits at none, so we pass.
The business posts just 2 percent revenue growth, 4 percent profit margins and 12 percent ROE. These are not the numbers of a compounder pulling away from rivals. A low multiple on peak cycle earnings often signals a value trap rather than a bargain, especially when demand for new vehicles can stall quickly.
Analyst targets sit around 131 while ethical screens clear. Still, thin growth and cyclical exposure keep the risk level elevated. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
VC trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 10.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (12 analysts) rates it buy, with a mean price target of $120. Since the last review it its composite score eased.
2026-10-29Markdown$72.42-14.6%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 14.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (12 analysts) rates it buy, with a mean price target of $120.
2026-10-22Markdown$84.83-4.3%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (12 analysts) rates it buy, with a mean price target of $120. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markdown$88.67+0.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (12 analysts) rates it buy, with a mean price target of $120. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Markdown$88.67+0.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (12 analysts) rates it buy, with a mean price target of $120. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Markdown$88.67+0.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (12 analysts) rates it buy, with a mean price target of $120. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markdown$88.67+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (12 analysts) rates it buy, with a mean price target of $120. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-17Markdown$88.67+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (12 analysts) rates it buy, with a mean price target of $120. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-16Markdown$88.67+3.8%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (12 analysts) rates it buy, with a mean price target of $120. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Markdown$85.43+0.0%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (12 analysts) rates it buy, with a mean price target of $120. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
